Dana Anton

Latest posts by Dana Anton (see all)

Efficacy of Levetiracetam in children with drug resistant partial seizures - 29/07/2015
EFICACITATEA TRATAMENTULUI CU LEVETIRACETAM LA COPIII CU CRIZE EPILEPTICE PARTIALE FARMACOREZISTENTE - 29/07/2015
Schönlein-Henoch purpura with neurological manifestations - 27/07/2015

Articole semnate de acelasi autor in Revista Romana de Pediatrie:

Efficacy of Levetiracetam in children with drug resistant partial seizures

Revista Romana de PEDIATRIE | Volumul LXI, Nr. 1, An 2012

ISSN 1454-0398 | e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

Georgeta Diaconu, Ioana Grigore, Laura Trandafir, Maria Iliescu, Mihaela Cioban and Dana Anton

ABSTRACT

Epilepsy is frequently diagnosed in the pediatric age raising numerous issues related to treatment. Levetiracetam (LEV) is an antiepileptic drug (AED) which is approved as a new combination therapy in different types of drug resistant seizures. The purpose of this study was to evaluate the efficacy and safety of LEV in combination with drug resistant therapy in partial epilepsies children. The study group included 63 children diagnosed with various forms of partial epilepsy. All patients received antiepileptic medication in monotherapy or polytherapy without remission of seizures. Levetiracetam has been associated with MAE initial dose of 10 mg/kg/day (two administrations), the dose was increased up to 40 mg/kg/day within 6 weeks. Patients were studied for a further period of six months. Among children who received associated LEV 34 (53.96%) showed a reduction > 50% of seizures, and 21 (33.35%) reduction was <50%. 8 (12.69%) of patients achieved complete control of critical episodes. Side effects recorded during the study were minimal, being represented by fatigue (12 cases), conduct disorder (7 cases), sleepiness at baseline (three cases), decreased appetite (4 cases), and vomiting (2 cases). Levetiracetam combination treatment in children with drug resistant partial epilepsy is effective with complete control or significant reduction in seizure frequency. Clinical response in the group of studied children was favorable especially in patients with partial motor seizures with or without secondary generalization. Levetiracetam was generally well tolerated, side effects occurred in the study being minimal.

Key words: Levetiracetam, child drug resistance, partial seizures

Full text | PDF

Georgeta Diaconu

EFICACITATEA TRATAMENTULUI CU LEVETIRACETAM LA COPIII CU CRIZE EPILEPTICE PARTIALE FARMACOREZISTENTE

ISSN 1454-0398 | e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

Georgeta Diaconu, Ioana Grigore, Laura Trandafir, Maria Iliescu, Mihaela Cioban and Dana Anton

REZUMAT

Epilepsia este frecvent diagnosticată la vârsta pediatrică, ridicând numeroase probleme legate de tratament. Levetiracetamul (LEV) este un medicament antiepileptic (MAE) nou care este aprobat ca tratament de asociere în diferite tipuri de crize epileptice farmacorezistente. Scopul acestui studiu a fost de a evalua eficacitatea şi siguranţa asocierii LEV în tratamentul epilepsiilor parţiale farmacorezistente la copii. Lotul de studiu a cuprins 63 de copii diagnosticaţi cu diferite forme de epilepsie parţială. Toţi pacienţii primeau medicaţie antiepileptică în mono sau politerapie fără remiterea crizelor. Levetiracetamul a fost asociat la MAE iniţială în doză de 10 mg/kg/zi (în două administrări), doză ce a fost crescută până la maxim 40 mg/kg/ zi în decurs de 6 săptămîni. Pacienţii au fost urmăriţi în continuare pe o perioadă de 6 luni. Dintre copiii urmăriţi la care s-a asociat LEV 34 (53,96%) au prezentat o reducere a crizelor cu >50%, iar la 21 (33,35%) reducerea a fost <50%. La 8 (12,69%) dintre pacienţi s-a obţinut controlul complet al episoadelor critice. Efectele secundare înregistrate pe durata studiului au fost minime, fiind reprezentate de fatigabilitate (12 cazuri), tulburări de comportament (7 cazuri), somnolenţă iniţială (3 cazuri), scăderea apetitului (4 cazuri), vărsături (2 cazuri). Asocierea LEV la tratamentul copiilor cu epilepsii parţiale farmacorezistente este eficientă în controlul complet sau în scăderea semnificativă a frecvenţei crizelor. Răspunsul clinic în grupul de copii studiat a fost favorabil în special la pacienţii cu crize parţiale motorii cu sau fără generalizare secundară. Levetiracetamul a fost în general bine tolerat, efectele secundare apărute în studiu fiind minime.

Cuvinte cheie: levetiracetam, crize epileptice parţiale farmacorezistente, copil

Full text | PDF

Georgeta Diaconu

Schönlein-Henoch purpura with neurological manifestations

Revista Romana de PEDIATRIE | Volumul LXI, Nr. 4, An 2012

ISSN 1454-0398 | e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

Georgeta Diaconu, Ioana Grigore, Dana Anton, Laura Trandafir and M. Burlea

ABSTRACT

Neurological symptoms represent possible manifestations of Schönlein-Henoch purpura. The authors present two children diagnosed with Schönlein-Henoch purpura. In booth cases the onset of disease was with neurological symptoms (epileptic seizures). In booth cases was observed behavioral problems and interictal EEG revealed abnormalities. In one case the neuroimaging exam revealed cerebral ischemic lesions. The authors consider that Schoenlein-Henoch purpura can involve the nervous system and review of the literature indicates that epileptic seizures and behavioral changes are the most frequent neurologic manifestations of this disease, followed by headache, focal neurologic deficits, mononeuropathies and polyradiculoneuropathies

Key words: Schönlein-Henoch purpura, epileptic seizures, behavioral problems

Full text | PDF

Georgeta Diaconu

PURPURA SCHONLEIN-HENOCH CU MANIFESTARI NEUROLOGICE

ISSN 1454-0398 | e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

Georgeta Diaconu, Ioana Grigore, Dana Anton, Laura Trandafir and M. Burlea

REZUMAT

Simptomele neurologice reprezintă manifestări posibile ale purpurei Schönlein-Henoch. Autorii prezintă doi copii diagnosticaţi cu purpură Schönlein-Henoch la care semnele de debut au fost neurologice, fiind reprezentate de crize epileptice. În ambele cazuri s-au asociat tulburări de comportament, iar EEG intercritic a evidenţiat grafoelemente patologice. Într-un caz examenul neuroimagistic cerebral a obiectivat leziuni ischemice cerebrale. Autorii confirmă că purpura Schönlein-Henoch poate interesa sistemul nervos, iar revederea literaturii arată că cele mai frecvente manifestări neurologice ale acestei boli sunt crizele epileptice şi tulburările de comportament, urmate de cefalee, deficite neurologice focale, mononeuropatii şi poliradiculoneuropatii

Cuvinte cheie: purpură Schönlein-Henoch, crize epileptice, tulburări de comportament

Full text | PDF

Georgeta Diaconu

Arhiva autor

Dana Anton

Latest posts by Dana Anton (see all)

Articole semnate de acelasi autor in Revista Romana de Pediatrie:

Efficacy of Levetiracetam in children with drug resistant partial seizures

SELECT ISSUE

Indexed

HIGHLIGHTS